All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-10-31T09:47:48.000Z

ESH 2019 | How will targeted therapies be used in the future?

By Andrew Wei
Featured
Andrew Wei
Oct 31, 2019
Share:

Bookmark this article

The AML Global Portal were delighted to speak to Andrew Wei, The Alfred Hospital, Victoria, AU, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Andrew Wei: How will targeted therapies be used in the future? He discusses the challenges of new therapeutic options and whether these should be combined or used sequentially with careful monitoring including MRD.

How will targeted therapies be used in the future?

More about...
ESH 2019

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 80 days left ...

Related articles

Add bookmark

ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew Wei, The Alfred Hospital, Melbourne, AU, and...

Feb 3, 2021
Add bookmark

ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew...

Feb 3, 2021
Add bookmark

ASH 2018 | Practice changing abstracts in acute myeloid leukemia 

Did you miss ASH 2018? The AML Global Portal has developed a downloadable resource, which provides information on the practice changing abstracts across acute myeloid leukemia.

Feb 13, 2019
Add bookmark

ASH 2018 | Practice changing abstracts in acute myeloid leukemia 

Did you miss ASH 2018? The AML Global Portal has developed a downloadable resource, which provides information on the practice...

Feb 13, 2019

Newsletter

Subscribe to get the best content related to AML delivered to your inbox